Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Analyst: Amazon Possibly Priming Itself As Medical Device Retailer

Executive Summary

The online retail giant has long been considered a potential threat to retail and mail-order pharmacists but, according to at least one analyst, the company may actually be gearing up to home-deliver medical devices to several states.

You may also be interested in...



CVS/Aetna To Merge In Defensive Play To Reshape Health-Care Delivery

The pharmacy retail chain and drug distributor will buy the insurer for $69bn in a merger to build what the companies say will be a new, more affordable health-care concept.

Amazon's Medtech Retail Plans: Analyst Finds More Evidence

Based on documents obtained by Jefferies, analysts say the view is clearer of Amazon's plans to conquer the medical device supply sector rather than challenging pharmaceutical retailers such as Walgreens and CVS for the time being.

'Excellence' In Health-Software Design: US FDA Taps Nine Firms To Figure Out What That Means

The likes of Apple, Samsung and FitBit join traditional medtech players Johnson & Johnson and Roche, along with digital-health startups in a new US FDA pilot program intended to define best-practice software design as a means to "pre-certify" companies and reduce pre-market requirements. FDA's Bakul Patel and the CEO of one pilot participant, Pear Therapeutics, weighs in.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT121699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel